Research Topics
Genomes and GenesSpecies | Matthew R CooperbergSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysisMatthew R Cooperberg
Departments of Urology and Epidemiology and Biostatistics, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
BJU Int 111:437-50. 2013..g. intensity-modulated RT for low-risk disease, were dominated - that is, both more expensive and less effective than competing alternatives...
Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohortMatthew R Cooperberg
University of California, San Francisco, Box 1695, 1600 Divisadero St, A 624, San Francisco, CA 94143 1695
J Clin Oncol 31:1428-34. 2013..The score may improve accuracy of risk stratification for men with clinically localized prostate cancer, including those with low-risk disease...- Time trends and local variation in primary treatment of localized prostate cancerMatthew R Cooperberg
University of California, San Francisco, Box 1695, 1600 Divisadero St, A 607, San Francisco, CA 94143 1695, USA
J Clin Oncol 28:1117-23. 2010..A critical need exists for high-quality comparative effectiveness research in localized prostate cancer to help guide treatment decision making... - Defining high quality health careMatthew R Cooperberg
Department of Urology, University of California, San Francisco, San Francisco, CA 94143, USA
Urol Oncol 27:411-6. 2009..It is crucial, therefore, that physicians assume increasing leadership roles in efforts to define, measure, report, and improve quality of care... - Risk assessment among prostate cancer patients receiving primary androgen deprivation therapyMatthew R Cooperberg
Department of Urology, University of California, San Francisco, 1600 Divisadero St, A 607, San Francisco, CA 94143 1695, USA
J Clin Oncol 27:4306-13. 2009..We compared risk features between large disease registries from the United States and Japan, and aimed to build and validate a risk prediction model applicable to PADT patients... 
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomyMatthew R Cooperberg
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
Cancer 107:2384-91. 2006..This study used a large external dataset to validate CAPRA...- High-risk prostate cancer in the United States, 1990-2007Matthew R Cooperberg
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115 1711, USA
World J Urol 26:211-8. 2008..This study aimed to describe national trends in presentation, management, and outcomes for men with high risk prostate cancer... - Treatment trends for stage I renal cell carcinomaMatthew R Cooperberg
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143 1695, USA
J Urol 186:394-9. 2011..Previous reports suggest that nephron sparing surgery is underused for small renal cell carcinomas. We determined updated, population based treatment trends for stage I renal cell carcinoma... - Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancerMatthew R Cooperberg
Department of Urology, University of California, San Francisco, CA, USA
Cancer 116:5226-34. 2010.... - Risk assessment for prostate cancer metastasis and mortality at the time of diagnosisMatthew R Cooperberg
Department of Urology, University of California San Francisco, 1600 Divisadero Street A 607, San Francisco, CA 94143 1695, USA
J Natl Cancer Inst 101:878-87. 2009.... - Active surveillance for prostate cancer: progress and promiseMatthew R Cooperberg
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
J Clin Oncol 29:3669-76. 2011..Ultimately, by minimizing the harms of overtreating low-risk prostate cancer, active surveillance may help settle the controversy surrounding prostate cancer screening and management... - The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomyMatthew R Cooperberg
Department of Urology, University of California, San Francisco, California, USA
Cancer 117:5039-46. 2011..They aimed to develop a similar postsurgical score with improved accuracy via incorporation of pathologic data... - The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomyMatthew R Cooperberg
University of California, San Francisco, San Francisco, USA
J Urol 173:1938-42. 2005..The concordance index for the UCSF-CAPRA score was 0.66. CONCLUSIONS: The UCSF-CAPRA score is a straightforward yet powerful preoperative risk assessment tool. It must be externally validated in future studies... - Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registryNatalia Sadetsky
Department of Urology, University of California, San Francisco, San Francisco, California, USA
Cancer 117:4406-13. 2011..In this study, the authors evaluated the effect of ADT administered as monotherapy and in combination with local treatment on physical well-being in a longitudinal sample of men with prostate cancer... - Changes in prostate cancer grade on serial biopsy in men undergoing active surveillanceSima P Porten
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St, Box 1695, San Francisco, CA 94143 1695, USA
J Clin Oncol 29:2795-800. 2011..Active surveillance is now considered a viable treatment option for men with low-risk prostate cancer. However, little is known regarding changes in Gleason grade on serial biopsies over an extended period of time... - The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancerJared M Whitson
Department of Urology, University of California San Francisco, San Francisco, California 94143, USA
J Urol 185:1656-60. 2011..We assessed whether an association exists between a change in prostate specific antigen and biopsy progression in men on active surveillance... - Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSUREJoseph A Mitchell
Department of Urology, Urology Outcomes Research Group, University of California, San Francisco, USA
J Urol 173:1126-31. 2005..This analysis suggests that simply estimating disease recurrence by stratifying patients into low, intermediate and high risk groups may not provide sufficient information for predicting outcomes among individuals... - Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSUREWilliam W Bassett
Department of Urology, Urologic Outcomes Research Group, University of California, School of Medicine, Comprehensive Cancer Center, San Francisco, California, USA
Urology 66:1060-5. 2005..Because of the increased comorbidities and greater rates of recurrence, obese individuals undergoing radical prostatectomy need vigilant follow-up care... - The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE)Jason W Anast
Department of Urology and UCSF/Mt. Zion Comprehensive Cancer Center, University of California, San Francisco, USA
J Urol 173:1132-8. 2005..Obese men have a similar recovery pattern of HRQOL after radical prostatectomy, with minimal additive long-term impairment in HRQOL relative to men of normal weight... - Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSUREDavid M Latini
Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group and UCSF Comprehensive Cancer Center, University of California, San Francisco, 94143, USA
Cancer 106:789-95. 2006..The present study examines the impact of Latino ethnicity on these parameters in a large, multiinstitutional database of men with prostate cancer... - Changes in specific domains of sexual function and sexual bother after radical prostatectomyJesse D Le
University of California San Francisco, San Francisco, CA, USA
BJU Int 106:1022-9. 2010.... - The changing face of low-risk prostate cancer: trends in clinical presentation and primary managementMatthew R Cooperberg
University of California San Francisco Mt Zion Cancer Center, 1600 Divisadero St, 3rd Floor, San Francisco, CA 94115-1711, USA
J Clin Oncol 22:2141-9. 2004..Overtreatment may be a growing problem, especially among older patients... - Active surveillance for the management of prostate cancer in a contemporary cohortMarc A Dall'Era
Department of Urology and the Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1695, USA
Cancer 112:2664-70. 2008..In this article, the authors report their experience in a contemporary cohort of men with prostate cancer who were managed with active surveillance... - Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized diseaseAdam C Reese
Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA
J Urol 184:114-9. 2010..We hypothesize that in the context of data available from a contemporary biopsy, clinical stage no longer offers meaningful independent prognostic information for clinically localized prostate cancer... - Outcomes of active surveillance for men with intermediate-risk prostate cancerMatthew R Cooperberg
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
J Clin Oncol 29:228-34. 2011..Current risk stratification schema identify patients with low-risk disease who are presumed to be most suitable for AS. However, some men with higher risk disease also elect AS; outcomes for such men have not been widely reported... - Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomyMichael L Eisenberg
Department of Urology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
Eur Urol 57:622-9. 2010..The prognostic meaning of an undetectable ultrasensitive prostate-specific antigen (USPSA) level after prostatectomy remains unclear... - Urologist density and county-level urologic cancer mortalityAnobel Y Odisho
Department of Urology, University of California, San Francisco, San Francisco, CA 94143 1695, USA
J Clin Oncol 28:2499-504. 2010..The goal of this study was to determine the effect of increasing urologist density on local prostate, bladder, and kidney cancer mortality... - Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURESusan R Harlan
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, UCSF/Mt. Zion Comprehensive Cancer Center, University of California-San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143, USA
J Urol 170:1804-7. 2003..We expect that as prostate cancer risk assessment and surveillance strategies continue to improve, more patients may benefit from this approach to management... - Who is the average patient presenting with prostate cancer?Kirsten L Greene
Department of Urology, UCSF Mt Zion Comprehensive Cancer Center, University of California San Francisco, California, USA
Urology 66:76-82. 2005..Patients report average or above-average pretreatment health-related QOL for all scales based on 2 validated instruments. In this cohort, more patients chose radical prostatectomy than any other form of treatment... - Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE)Matthew R Cooperberg
Department of Urology, UCSF/Mt. Zion Comprehensive Cancer Center, University of California, San Francisco 94115-1711, USA
J Urol 170:S21-5; discussion S26-7. 2003..This shift is most likely attributable to changes in practice patterns with respect to screening and pathological grading. These changes should be considered when applying nomograms derived from earlier datasets to contemporary cases... - The quantitative Gleason score improves prostate cancer risk assessmentAdam C Reese
Department of Urology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143 1695, USA
Cancer 118:6046-54. 2012..They hypothesize that the qGS can improve prostate cancer risk stratification and help prevent the overtreatment of patients with clinically indolent tumors... - Adequacy of lymphadenectomy among men undergoing robot-assisted laparoscopic radical prostatectomyMatthew R Cooperberg
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA
BJU Int 105:88-92. 2010..To compare rates of lymph node dissection (LND) and nodal yields between patients treated with open radical retropubic prostatectomy (ORRP) and robot-assisted RRP (RARP) in a contemporary single-institution series... - Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores?Sanoj Punnen
Department of Urology, University of California, San Francisco, CA, USA
BJU Int 109:1520-4. 2012..This suggests that the current definition of potency, inclusive of medication use, is valid with respect to sexual bother... - Inaccuracies in assignment of clinical stage for localized prostate cancerAdam C Reese
Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
Cancer 117:283-9. 2011..One explanation for this lack of predictive power may be the inaccurate application of staging criteria... - National practice patterns and time trends in androgen ablation for localized prostate cancerMatthew R Cooperberg
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California, San Francisco (UCSF)/Mt. Zion Comprehensive Cancer Center, UCSF, San Francisco 941150-1711, USA
J Natl Cancer Inst 95:981-9. 2003..Future clinical trials must define more clearly the appropriate role of hormonal therapy in localized prostate cancer, and their results should shape updated practice guidelines... - Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure)Kirsten L Greene
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco 94115-1711, USA
J Urol 171:2255-9. 2004..Further refinements in pretreatment estimation of disease-free survival and ultimately overall survival are needed... - Active surveillance for prostate cancer: a systematic review of the literatureMarc A Dall'Era
Department of Urology, University of California Davis Medical Center, Sacramento, CA 95817, USA
Eur Urol 62:976-83. 2012..Prostate cancer (PCa) remains an increasingly common malignancy worldwide. The optimal management of clinically localized, early-stage disease remains unknown, and profound quality of life issues surround PCa interventions... - Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physiciansGregory E Tasian
Department of Urology, University of California, San Francisco, CA 94143, USA
Urol Oncol 30:155-60. 2012.... - Patients with primary hyperparathyroidism--why do some form stones?Aaron D Berger
Department of Urology, University of California San Francisco, San Francisco, California, USA
J Urol 181:2141-5. 2009..We evaluated the metabolic stone profile in patients presenting for parathyroid surgery and determined whether there were differences between those with and without a history of urinary stones... - The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registryMatthew R Cooperberg
Department of Urology, University of California-San Francisco/Mt Zion Comprehensive Cancer Center, San Francisco, California 94115-1711, USA
J Urol 171:1393-401. 2004..CaPSURE will continue to track these trends as well as oncological and quality of life outcomes, and will continue to be an invaluable resource for the study of prostate cancer at the national level... - Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004Matthew R Cooperberg
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA
J Urol 179:2131-5. 2008..The proportion of renal cell carcinoma cases diagnosed at stage I is known to be increasing significantly. We characterized stage I tumors further in terms of tumor size at diagnosis using a large national cancer registry... - The example of CaPSURE: lessons learned from a national disease registrySima P Porten
Department of Urology, UCSF Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA
World J Urol 29:265-71. 2011.... - The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized diseaseSima P Porten
Department of Urology, University of California, San Francisco, USA
BJU Int 105:472-5. 2010.... - In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CTYoungho Seo
Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143 0946, USA
J Nucl Med 51:31-6. 2010..We have developed an in vivo method to quantify antibody uptake using (111)In-capromab pendetide SPECT combined with CT (SPECT/CT). Our goal was to evaluate this method for potential grading of prostate tumors... - Active surveillance for early-stage prostate cancer: review of the current literatureMarc A Dall'Era
Department of Urology, University of California at San Francisco Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1695, USA
Cancer 112:1650-9. 2008..The best candidates for active surveillance are being defined, as are predictors of active treatment. The psychosocial ramifications of surveillance for prostate cancer can be profound and future needs and unmet goals will be discussed... - Prostate cancer 2004: insights from national disease registriesMatthew R Cooperberg
Department of Urology, Program in Urologic Oncology, University of California San Francisco, California 94115-1711, USA
Oncology (Williston Park) 18:1239-47; discussion 1248-50, 1256-8. 2004..The availability of these large databases of patients will be a tremendous asset as prostate cancer management continues to evolve in the coming years... - How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSUREMatthew R Cooperberg
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California, San Francisco Mt Zion Comprehensive Cancer Center, San Francisco, California 94143, USA
Urology 61:190-6. 2003..The accurate assessment of sexual function is critical for the evaluation of outcomes after treatment of prostate cancer. The assessments of potency typically used in this context, however, may be oversimplified... - Obesity and prostate cancer clinical risk factors at presentation: data from CaPSUREChristopher J Kane
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco, USA
J Urol 173:732-6. 2005..We investigated the association of obesity with prostate cancer case demographics and clinical disease features at presentation... - Androgen deprivation therapy and cardiovascular riskSanoj Punnen
University of California, San Francisco, Department of Urology, 1600 Divisadero St, Box 1695, San Francisco, CA 94143 1695, USA
J Clin Oncol 29:3510-6. 2011..This study assessed mortality outcomes in a large national registry to further elucidate the association between treatment selection and cause of mortality... - Factors associated with downgrading in patients with high grade prostate cancerJared M Whitson
Department of Urology, University of California San Francisco, San Francisco, CA 94143, USA Electronic address
Urol Oncol 31:442-7. 2013..To determine the factors associated with downgrading between biopsy and prostatectomy in the contemporary era using extended-template biopsy techniques... - Disproportionate presentation of high risk prostate cancer in a safety net health systemSima P Porten
Department of Urology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center and San Francisco General Hospital, San Francisco, California 94143 1695, USA
J Urol 184:1931-6. 2010..We describe prostate cancer characteristics in men treated in a public health system and hypothesize a disproportionate burden of high risk disease in this population... - Contemporary trends in low risk prostate cancer: risk assessment and treatmentMatthew R Cooperberg
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94115, USA
J Urol 178:S14-9. 2007..We updated national risk trends in prostate cancer with a focus on low risk tumors, reexamined trends in primary treatment for low risk tumors and substratified patients at low risk based on pretreatment clinical data... - Impact of age at diagnosis on prostate cancer treatment and survivalSeth K Bechis
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143 1695, USA
J Clin Oncol 29:235-41. 2011..As a result, age often plays a role in treatment choice. However, the relationships among age, disease risk, and prostate cancer-specific survival have not been well established... - Geographic distribution of urologists throughout the United States using a county level approachAnobel Y Odisho
Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143 1695, USA
J Urol 181:760-5; discussion 765-6. 2009..We assessed the geographic distribution of urologists throughout the United States at the county level and determined the county characteristics associated with increased urologist density... - Patterns of practice in the United States: insights from CaPSURE on prostate cancer managementMatthew R Cooperberg
University of California, San Francisco, Mount Zion Cancer Center, 1600 Divisadero Street, 6th Floor, San Francisco, CA 94115-1711, USA
Curr Urol Rep 5:166-72. 2004.... - Health related quality of life in patients treated with multimodal therapy for prostate cancerAlex K Wu
Department of Urology, University of California, San Francisco, San Francisco, California 94143 1695, USA
J Urol 180:2415-22; discussion 2422. 2008..However, the effects of multimodal therapy on health related quality of life have not been comprehensively described. We further characterized health related quality of life in patients treated with multimodal therapy... - Candidate quality of care indicators for localized bladder cancerMatthew R Cooperberg
Department of Urology, University of California, San Francisco, San Francisco, CA 94143, USA
Urol Oncol 27:435-42. 2009..The urologic oncology community should take a strong lead in achieving consensus regarding the definition, assessment, and reporting of quality of care data for bladder cancer... - Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine CytologyAnobel Y Odisho
Department of Urology and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA
Eur Urol 63:936-40. 2013.... - Adequacy of a single 24-hour urine collection for metabolic evaluation of recurrent nephrolithiasisScott M Castle
Department of Urology, University of California San Francisco, San Francisco, California, USA
J Urol 184:579-83. 2010..We determined whether repeat 24-hour urine collection provides information similar to that of the initial 24-hour urine collection and whether repeat collection is necessary... - High-risk nonmuscle invasive bladder cancer: definition and epidemiologySima P Porten
Department of Urology, UCSF Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California, USA
Curr Opin Urol 22:385-9. 2012..Precise definition and risk stratification are paramount in this group as high-risk patients have higher rates of progression and mortality and may benefit from early identification and aggressive treatment... - Management of localized prostate cancer in men over 65 yearsMatthew R Cooperberg
Department of Urology, University of California, San Francisco, CA 94143 1695, USA
Curr Opin Urol 19:309-14. 2009..However, the majority of tumors are still detected among men over 65-years-old. The appropriate management of localized disease among these older men is controversial... - Gender differences in subcutaneous and perirenal fat distributionBrian H Eisner
Department of Urology, GRB 1102, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
Surg Radiol Anat 32:879-82. 2010..Body mass index (BMI) has been shown to influence the outcome of various surgical procedures. The purpose of this study is to assess the relationship between BMI, gender, and the distribution of subcutaneous and perirenal fat... - Radical retropubic prostatectomy frustrated by prior laparoscopic mesh herniorrhaphyMatthew R Cooperberg
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, UCSF/Mt Zion Comprehensive Cancer Center, University of California-San Francisco, 1600 Divisadero Street 3rd Floor, San Francisco, CA 94115-1711, USA
Surgery 135:452-3; discussion 454. 2004 - Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavorMatthew R Cooperberg
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco/Mt. Zion Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California, USA
J Urol 168:491-5. 2002.... - Health related quality of life significance of single pad urinary incontinence following radical prostatectomyMatthew R Cooperberg
Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco/Mt. Zion Comprehensive Cancer Center, 94115-1711, USA
J Urol 170:512-5. 2003..We believe that these findings underscore the need for more comprehensive HRQOL assessment in urinary outcome assessment after prostatectomy... - Oral calcium supplementation associated with decreased likelihood of nephrolithiasis prior to surgery for hyperparathyroidismMatthew R Cooperberg
Department of Urology, University of California, San Francisco, San Francisco, California 94143, USA
Int J Urol 14:1113-5. 2007..027; women 7% vs 17%, P = 0.04). The mechanism for the apparent protective effect of OCS on rates of nephrolithiasis is unclear, and further research is required to elucidate the variable penetrance of nephrolithiasis among PHPT patients... - Variability in testis biopsy interpretation: implications for male infertility care in the era of intracytoplasmic sperm injectionMatthew R Cooperberg
Department of Urology, University of California San Francisco, California, USA
Fertil Steril 84:672-7. 2005..These differences contribute to inaccurate phenotyping of male infertility and can significantly impact the direction of infertility care. These findings highlight the need for a standardized approach to testis histologic review... - Laparoscopic management of peripelvic renal cysts: University of California, San Francisco, experience and review of literatureAffonso H L A Camargo
Department of Urology, University of California, San Francisco, School of Medicine, San Francisco, California 94143-0738, USA
Urology 65:882-7. 2005..In addition to our experience, a thorough review of published reports found this procedure to be safe and effective with appropriate patient selection... - The changing face of prostate cancerMatthew R Cooperberg
Department of Urology, UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115-1711, USA
J Clin Oncol 23:8146-51. 2005.... - Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cellsBin Liu
Department of Anesthesia and Pharmaceutical Chemistry, University of California at San Francisco, San Francisco General Hospital, California, USA
Cancer Res 64:704-10. 2004..Targeting components of this epitope space may facilitate development of immunotherapeutic and small molecule-based strategies as well as the use of other therapeutic agents that rely upon delivery to the interior of the tumor cell... - Trends in regionalization of inpatient care for urological malignancies, 1988 to 2002Matthew R Cooperberg
Urologic Outcomes Research Group, Program in Urologic Oncology, Department of Urology, University of California San Francisco Comprehensive Cancer Center, California 94115 1711, USA
J Urol 178:2103-8; discussion 2108. 2007..The net effect of these pressures may be the regionalization of care. We quantified trends in the regionalization of inpatient care for urological oncology in a national administrative database... - Renal cell cancer stage migration: analysis of the National Cancer Data BaseChristopher J Kane
Division of Urology, Department of Surgery, University of California at San Diego Medical Center, San Diego, CA 92103 8897, USA
Cancer 113:78-83. 2008..The aim of the study was to analyze patterns of disease presentation and outcome of RCC by AJCC stage using data from the National Cancer Data Base (NCDB) over a 12-year period...